UK Clinical Trial Application submitted for amyloid-targeting drug
The Clinical Trial Application sent to the MHRA is for a combination drug with the potential to become a cost-effective treatment against early Alzheimer’s disease.
List view / Grid view
The Clinical Trial Application sent to the MHRA is for a combination drug with the potential to become a cost-effective treatment against early Alzheimer’s disease.
European Pharmaceutical Review explores how a surge in the number of warning letters for data integrity failings have prompted regulators to publish new guidelines.
The Medicines and Healthcare products Regulatory Agency has issed two alerts for medicine recalls in the UK due to out of specification dissolution results and an error in decommissioning.
The UK healthcare agency has issued an alert for Perrigo ranitidine products, recalling and quarantining certain batches.